Out­spo­ken drug pric­ing re­searcher Pe­ter Bach takes CMO gig at liq­uid biop­sy start­up

Af­ter spend­ing more than a decade crit­i­ciz­ing the in­dus­try over drug pric­ing, Memo­r­i­al Sloan Ket­ter­ing’s out­spo­ken re­searcher Pe­ter Bach is jump­ing over to the C-suite of a liq­uid biop­sy start­up.

Bach, known for his frank tweets and fre­quent ed­i­to­ri­als, is tak­ing the CMO role at Delfi Di­ag­nos­tics, a Bal­ti­more-based biotech that’s look­ing for a bet­ter way to screen the blood for can­cer. The com­pa­ny snagged $100 mil­lion at the be­gin­ning of the year, and a cou­ple months ago ini­ti­at­ed a na­tion­al tri­al for lung can­cer screen­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER